Ironwood Pharmaceuticals, Inc. (FRA:I76)

Market Cap	567.81M
Revenue (ttm)	288.92M
Net Income (ttm)	24.33M
Shares Out	n/a
EPS (ttm)	0.15
PE Ratio	23.34
Forward PE	5.04
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	404
Open	3.480
Previous Close	3.440
Day's Range	3.480 - 3.480
52-Week Range	0.478 - 4.520
Beta	n/a
RSI	55.51
Earnings Date	Feb 17, 2026

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-...

• Industry: Pharmaceutical Preparations
• Founded: 1998
• Employees: 253
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: I76

Financial Performance

Financial numbers in USD